Clinical Trials Logo
  1. Home
  2. Male Breast Cancer
  3. NCT03240510
  4. Details
NCT03240510 Clinical Trial

Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience

Male Breast Cancer Clinical Trial

Official title:
Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience

Clinical Trial Details — Status: Active, not recruiting

Administrative data
NCT number NCT03240510
Other study ID # SalahSCI
Secondary ID
Status Active, not recruiting
Phase N/A
First received July 28, 2017
Last updated August 1, 2017
Start date January 1, 2014
Est. completion date January 1, 2018

Study information
Verified date August 2017
Source Salah Azaïz Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this study is to evaluate the Salah Azaïz Cancer Institute male breast cancer patients population over a period of 14 years.

Goal of the retrospective part: to gather clinicopathologic data and follow-up outcomes of male breast cancer patients diagnosed and/or treated at Salah Azaïz Cancer Institute from 2004 to 2013.

Goal of the prospective part: to create a registry of male patients with breast cancer for a period of 48 months (from 2014 to 2017).

Recruitment information / eligibility
Status Active, not recruiting
Enrollment 150
Est. completion date January 1, 2018
Est. primary completion date December 31, 2016
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria:

Histological diagnosis of male breast cancer

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Tunisia Salah Azaïz Cancer Institute Tunis

Sponsors (1)
Lead Sponsor Collaborator
Salah Azaïz Cancer Institute

Country where clinical trial is conducted

Tunisia, 

Outcome
Type Measure Description Time frame Safety issue
Primary Clinical outcomes Survival, Disease free survival Through study completion, an average of 4 year
Primary Clinico-biological characteristics of the disease Through study completion, an average of 4 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02480933 - Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens N/A
Terminated NCT01705340 - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Phase 1
Terminated NCT01222377 - Endoscopic Breast Surgery in Treating Patients With Breast Cancer N/A
Completed NCT00425672 - ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment Phase 1/Phase 2
Completed NCT00244881 - A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202) Phase 2
Completed NCT00096434 - Sorafenib in Treating Patients With Metastatic Breast Cancer Phase 2
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Completed NCT01037790 - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer Phase 2
Active, not recruiting NCT00791037 - Vaccine Therapy in Treating Patients With Stage IV Breast Cancer Phase 1/Phase 2
Completed NCT00559507 - Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery Phase 2
Completed NCT00119262 - Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer Phase 2
Completed NCT00098605 - Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases Phase 2
Terminated NCT00095888 - 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer Phase 2
Terminated NCT00071942 - Vaccine Therapy in Treating Patients With Metastatic Breast Cancer Phase 1
Completed NCT00068588 - GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer Phase 2
Recruiting NCT05501704 - ETHAN - ET for Male BC Phase 2
Completed NCT02046421 - Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Phase 1
Completed NCT01869764 - Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer Phase 2
Completed NCT01720602 - Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy N/A
Terminated NCT01931709 - FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer N/A